Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma
Abstract Bispecific antibodies (BsAbs) have shown promise in the management of relapsed/refractory multiple myeloma (MM). Despite its efficacy, this class of drugs is associated with significant toxicities. In this study, we conducted a pooled analysis of the available clinical trials on BsAbs for t...
Saved in:
| Main Authors: | Mobina Golmohammadi, Shahzad Raza, Maram Albayyadhi, Hossein Sholehrasa, Jack Khouri, Louis Williams, Doris K. Hansen, Azam Moradi, Xuan Xu, Moath Albliwi, Ali Hajj Ali, Danai Dima, Faiz Anwer, Barry Paul, Majid Jaberi-Douraki |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-08-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-025-01334-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
by: Alfred L. Garfall, et al.
Published: (2025-07-01) -
The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma
by: Xiaoling Zhou, et al.
Published: (2025-08-01) -
Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma
by: Brandon Tedder, et al.
Published: (2025-07-01) -
Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
by: Benjamin Adegbite, et al.
Published: (2025-08-01) -
Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis
by: Dan Liu, et al.
Published: (2024-11-01)